长江商报消息 ●长江商报记者 黄聪 盈利转正后，百济神州（688235.SH、06160.HK、NASDAQ:BGNE）爆发出巨大的增长动力。 2月27日，百济神州发布业绩快报显示，公司2025年营业收入达382.05亿元，同比增长40.4%，其中产品收入达 377.7亿元，同比增长39.9%。同期，公司归母净利润达14.22亿元，上年同期亏损49.78亿元。 长江商报记者发现，百济神州研发费用已连续四年超过100亿元。近四年来，公司研发费用累计达492.64亿元，占 同期营业收入比例约60%。 进入2025年，百济神州业绩出现好转，除了一季度归母净利润亏损9450.3万元外，二季度和三季度归母净利润分 别为5.44亿元和6.89亿元。 百济神州介绍，2025年，公司产品收入的增长主要得益于百悦泽^?（泽布替尼），以及安进公司授权产品和百泽 安^?（替雷利珠单抗）的销售增长。 2025年，百悦泽^?全球销售额总计280.67亿元，同比增长48.8%，已在BTK抑制剂领域稳固确立全球领导者的地 位。其广泛的监管批准、持续深化的全球布局、临床医生的高度认可，以及在慢性淋巴细胞白血病（CLL）领域 卓越的长期疗效与 ...

Iovance Biotherapeutics (NASDAQ:IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas.This news has energized investors as the broader market is experiencing gains, with the Nasdaq up 0.51%.Among the first six evaluable patients treated with lifileucel monotherapy, the trial showed a 50% confirmed objective response rate (ORR).The trial, conducted by Memorial Sloan Kettering Cancer Center, f ...

Eli Lilly and Co. (NYSE:LLY) on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for Retevmo (selpercatinib). The trial demonstrated a highly statistically significant improvement in event-free survival for patients with early-stage non-small cell lung cancer. Lung Cancer Trial Shows Benefit The LIBRETTO-432 trial results showed that selpercatinib significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cance ...

Group 1 - The core point of the article is that the first patient has successfully received treatment with the drug Opalizumab (LBL-024) in a Phase Ib/II clinical trial for recurrent or metastatic triple-negative breast cancer (TNBC) [1] - The clinical trial is an open-label, multi-center study led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital, aiming to evaluate the efficacy and safety of Opalizumab alone or in combination with albumin-bound paclitaxel for TNBC patients [1] - The drug Opalizumab is a bispecific antibody targeting both PD-L1 and 4-1BB, and it is the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage for extra-pulmonary neuroendocrine carcinoma [2] Group 2 - In two clinical trials in China, Opalizumab has shown encouraging efficacy signals and good safety profiles, whether used as a monotherapy or in combination with chemotherapy for advanced extra-pulmonary neuroendocrine carcinoma [3] - The company received approval from the National Medical Products Administration (NMPA) in April 2024 to conduct a single-arm registration clinical trial and obtained breakthrough therapy designation (BTD) in October 2024 for treating advanced extra-pulmonary neuroendocrine carcinoma [3] - Cancer is a leading cause of morbidity and mortality globally, with breast cancer being the second most common cancer after lung cancer, and TNBC represents a subtype with high malignancy and poor prognosis, accounting for about 15% to 20% of all breast cancer cases [4]

Core Viewpoint - The announcement highlights the successful administration of the first patient in a Phase Ib/II clinical trial for the treatment of recurrent or metastatic triple-negative breast cancer (TNBC) using the bispecific antibody, Opalizumab (LBL-024), which targets PD-L1 and 4-1BB [1] Group 1: Clinical Trial and Drug Development - The Phase Ib/II clinical trial is an open-label, multicenter study led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital, aiming to evaluate the efficacy and safety of Opalizumab alone or in combination with albumin-bound paclitaxel for TNBC patients [1] - Opalizumab is the first bispecific antibody targeting both PD-L1 and 4-1BB, showing potential as a leading therapy for advanced pulmonary neuroendocrine carcinoma and demonstrating promising clinical activity in various indications [1][2] - The drug has received several regulatory designations, including Breakthrough Therapy Designation (BTD) from the NMPA in October 2024 and Orphan Drug Designation from the FDA in November 2024 for neuroendocrine carcinoma [2] Group 2: Market Need and Cancer Statistics - Cancer remains a leading cause of morbidity and mortality globally, with breast cancer being the second most common cancer, accounting for approximately 2.3 million new cases annually [3] - In China, the incidence of breast cancer continues to rise, with an estimated 360,000 new cases and 75,000 deaths each year, highlighting the urgent need for effective treatments, particularly for TNBC, which represents 15% to 20% of all breast cancer cases [3] - TNBC is characterized by high malignancy, recurrence rates, and poor prognosis, indicating a significant unmet clinical need for more effective treatment options beyond standard chemotherapy [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） 維 利 信™是一種同時靶向PD-L1與4-1BB的 雙 特 異 性 抗 體，為 針 對 肺 外 神 經 內 分泌癌的全球首款達到註冊臨床階段的靶向4-1BB受 體 的 療 法。於 非 小 細 胞 肺 癌、小 細 胞 肺 癌 及 肺 外 神 經 內 分 泌 癌 這3種適應症的II期 或 註 冊 臨 床 試 驗 中， 維 利 信™展 現 出 同 類 第 一 或 同 類 最 佳 臨 床 活 性 潛 力。維 利 信™亦有望成為治療 晚 期 肺 外 神 經 內 分 泌 癌 的 首 款 獲 批 藥 物。憑 藉 我 們 自 主 研 發 並 具 有 知 識 產 ...

Core Viewpoint - The 27th "World Cancer Day" on February 4, 2026, emphasizes a human-centered approach to cancer prevention, screening, and treatment, highlighting that one-third of cancers are preventable and one-third are curable [1] Group 1: Cancer Prevention - Smoking cessation and avoiding secondhand smoke are crucial, as smoking is the primary cause of lung cancer; quitting smoking can reduce lung cancer risk by 50% after 10-15 years [1] - A balanced diet rich in fresh fruits, vegetables, whole grains, and quality proteins is essential; avoiding moldy foods, high-salt preserved foods, and processed meats can lower cancer risk [1] - Regular physical activity of at least 150 minutes per week and limiting alcohol consumption are recommended to reduce the risk of various cancers [1] Group 2: Early Detection - Regular screening is vital for early cancer detection, with specific recommendations for different types of cancer: - Lung cancer screening for individuals over 50 with a smoking history of 20 pack-years, using low-dose spiral CT annually [2] - Colorectal cancer screening starting at age 45 with fecal occult blood tests and colonoscopy if results are abnormal [3] - Stomach cancer screening for individuals over 40 in high-risk areas or those infected with Helicobacter pylori, using regular gastroscopy [4] - Liver cancer screening for long-term drinkers and patients with hepatitis B or cirrhosis, with semi-annual serum alpha-fetoprotein tests and liver ultrasounds [5] - Breast cancer screening for women starting at age 40 with mammograms every 1-2 years, and high-risk women starting at age 35 annually [6] - Cervical cancer screening for women over 25 with cytology tests, and HPV testing for those over 30 [7] - Prostate cancer screening for men starting at age 50 every 2 years, and high-risk men starting at age 45 annually with PSA tests and digital rectal exams [8] Group 3: Treatment and Support - Upon cancer diagnosis, patients should avoid pseudoscientific treatments and seek care from reputable medical institutions, utilizing precision radiotherapy and targeted therapies to improve survival rates and quality of life [9] - Psychological support is crucial during cancer treatment, with professional counseling, peer support, music therapy, and rehabilitation exercises recommended to enhance mental and physical well-being [9] - The call for collective societal effort emphasizes that everyone should take responsibility for their health, combining healthy habits, proactive screening, scientific treatment, and social support to build a comprehensive defense against cancer [9]

Group 1 - Merck has ceased discussions regarding the acquisition of Revolution Medicines, which was previously valued at approximately $30 billion [1] - Negotiations cooled due to a lack of agreement on price, but there is potential for talks to resume or for other buyers to emerge [1] - Revolution Medicines is expected to release trial data for its pancreatic and colorectal cancer drug candidates in the first half of this year [1] Group 2 - Merck's CEO stated that the company is primarily focused on transactions under $15 billion but is open to larger acquisitions while maintaining a cautious approach [2] - Revolution Medicines is developing drugs targeting RAS-driven cancers, which have been challenging to treat due to technical difficulties [2] - If Revolution's pancreatic cancer drug candidate proves safe and effective, it could achieve global sales of $10 billion by 2035, dominating the treatment of this disease [2] Group 3 - The cancer treatment market is one of the most important and profitable sectors in the pharmaceutical industry, with global sales of cancer drugs exceeding $240 billion last year [2]

Group 1 - Merck (MRK.US) has halted acquisition talks with Revolution Medicines (RVMD.US) due to disagreements over the purchase price, which was estimated to value Revolution Medicines at around $30 billion [1] - Merck is seeking to strengthen its treatment portfolio to address an anticipated $18 billion loss in sales over the next five years due to patent expirations, particularly with its key cancer drug Keytruda losing patent protection by the end of this decade [1] - The potential acquisition could have provided Merck with Revolution Medicines' experimental drug Daraxonrasib, which is a key asset for the company [1][2] Group 2 - Daraxonrasib (RMC-6236) is an oral targeted drug that acts as a multi-selective inhibitor of RAS, aimed at treating cancers driven by RAS gene mutations [2] - The drug targets common oncogenic RAS mutations, including G12X, G13X, and Q61X, which are significant drivers of major cancers such as pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) [2] - Daraxonrasib is currently being evaluated in four global Phase 3 clinical trials, including three studies focused on PDAC and one on locally advanced or metastatic RAS-mutant NSCLC, with key results expected to be announced this summer [2][3] Group 3 - The RASolute304 clinical trial, which is a global, open-label Phase 3 study, aims to assess the safety and efficacy of Daraxonrasib in resectable PDAC patients who have undergone surgery and chemotherapy [3] - The trial plans to enroll approximately 500 patients with oncogenic RAS mutations who have completed tumor resection and perioperative chemotherapy [3] - Industry research indicates that the pancreatic cancer treatment market could expand tenfold to over $3 billion by 2035, driven by Daraxonrasib, which is expected to receive FDA approval by 2026 [3]

Core Viewpoint - Recent research indicates that crotonate, a short-chain fatty acid, has potential as a candidate drug for inhibiting breast cancer growth and metastasis by inducing specific modifications in the EZH2 protein, enhancing responses to immunotherapy [4][9]. Group 1: Research Findings - Crotonate suppresses breast cancer metastasis and promotes immunotherapy response through ACSS2-mediated EZH2-K348 crotonylation [3][4]. - The study reveals a new pathway where crotonate leads to the degradation of EZH2 protein via crotonylation at the K348 site, resulting in decreased levels of H3K27me3 [6][8]. - Compared to the EZH2 inhibitor tazemetostat, crotonate shows superior efficacy in inhibiting breast cancer metastasis [8]. Group 2: Mechanism of Action - Crotonate is metabolized to crotonyl-CoA, which then induces the crotonylation of EZH2, leading to its ubiquitin-mediated degradation [6][9]. - The mechanism involves the action of acetyltransferase p300, which catalyzes the formation of EZH2-K348cr, promoting the degradation of the modified EZH2 protein [6][8].